Navigation Links
Nanocopoeia Licenses New Polymer-Based Biomaterials Platform From the University of Western Ontario
Date:6/26/2008

Follows the launch of their first partnership venture, NanoInterventions,

at BIO International

ST. PAUL, Minn. and LONDON, Ontario, June 26 /PRNewswire/ -- Following the launch at BIO International in San Diego last week of NanoInterventions, their cardiovascular joint venture partnership, Nanocopoeia and WORLDiscoveries(TM) are pleased to announce their broader agreement to co-develop the biomedical uses of arborescent polyisobutylene-based block copolymers. Nanocopoeia, a drug delivery company specializing in therapeutic coatings for medical devices, will lead the development effort and WORLDiscoveries(TM) will participate as a partner in the market-targeted applications. The agreement includes an exclusive world-wide license, for all biomedical fields of use, for the polymer system that is the subject of US Patent No. 6,747,098 (2004) and nine other international issued patents.

Arborescent polyisobutylene-based block copolymers are branched polymers with unique properties for biomedical use. A major market opportunity is their use as a drug-eluting coating for medical devices such as coronary stents. When applied using Nanocopoeia's proprietary ElectroNanospray(TM) process, the polymer provides a highly controllable matrix for drug delivery and has excellent physical properties. For other applications, such as tissue implants, this family of polymers has many attributes in common with silicone materials but without the need of the additional chemicals that are required to formulate silicone-based devices.

Judit E. Puskas, PhD, P.Eng, led the team at Western that invented the family of polymers based on arborescent polyisobutylene. She held the Bayer/NSERC (Natural Science and Engineering Research Council of Canada) Industrial Research Chair at Western between 1998 and 2003, and is now Professor of Polymer Science at The University of Akron in Ohio. Dr. Puskas commented, "This polymer system has enormous flexibility in the way it can be applied, while remaining totally stable. That, together with the favorable biocompatibility profile of its building blocks, makes it an ideal interface with body tissues." Dr. Puskas will participate in the joint development program.

Nanocopoeia's drug delivery and coating technology uses the proprietary ElectroNanospray(TM) process to apply nanoparticle-based coatings. The unique process, which originated at the University of Minnesota, generates nanoparticles made of drugs and polymers and assembles them into films with controllable delivery.

The National Science Foundation's research funding has played an important role in launching the collaboration. The commercial development of Nanocopoeia's ElectroNanospray(TM) technology for biomedical applications has been supported through multiple SBIR Phase II and supplemental awards from the NSF Division of Industrial Innovation and Partnerships. In the course of that research, the Company's search for novel coating polymer systems led them to Dr. Puskas, resulting in the ongoing productive collaboration. Dr. Puskas' research is supported by the NSF Division of Materials Research.

Nanocopoeia's CEO, Robert A. Hoerr, MD, PhD, said, "Based on our success in working with this polymer system, we believe it will have applicability for a broad range of biomedical uses." He further commented that a first use of the polymer has been as a prototype drug-eluting stent coating based on arborescent polyisobutylene-block-polystyrene (abbreviated arbIBS) used by the joint venture NanoInterventions for its Mouse Stent Model. He continued, "Given the strong interest that NanoInterventions' Mouse Stent Model generated at BIO, we believe the polymer will be a key element in helping us to define next generation of stent-delivered therapies."

NanoInterventions is a joint venture partnership that is launching the first rapid screening model for new coronary stent coatings, using a genetically modified mouse strain with human-like atherosclerosis, a mini- stent, and experimental coatings on the stent. Joint venture partners other than Nanocopoeia and Western include Stentome, LLC, an interventional cardiology company based in Palo Alto, CA, Oxford, UK, and Galway, Ireland, and The Integra Group, a medical research organization based in Brooklyn Park, MN, that provides a full range of preclinical and clinical development services. NanoInterventions was a featured company in the Positively Minnesota pavilion in the BIO International exhibition hall, from June 17-20, 2008.

With annual research expenditures of more than $223 million and an international reputation for success, The University of Western Ontario ranks as one of the top ten research-intensive universities in Canada. Offering Canada's best student experience among its peers, Western and its affiliated research institutes provide a culture that encourages entrepreneurial research and innovation.

WORLDiscoveries(TM) is a joint venture between Lawson Health Research Institute and The University of Western Ontario, including Robarts Research Institute, that capitalizes on the institutions' combined research strengths related to medical and health-related sciences, energy and the environment and new materials. The London region is recognized as a national leader in these key areas, and the city has identified them as opportunities for further growth.

Rob Herold, Associate Director of Western's Industrial Liaison Office, commented, "The innovative structure of our licensing partnership with Nanocopoeia lets us participate in the evolving healthcare applications of this polymer platform. WORLDiscoveries(TM) was structured to enable us work with highly entrepreneurial companies like Nanocopoeia and share in their upside potential, in addition to the standard licensing process that we have traditionally used. We have great confidence both in the technology and in our new partner."


'/>"/>
SOURCE Nanocopoeia
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
2. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
3. Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
4. USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical
5. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
6. Japan Patent Office Licenses GeneCards(R) from Xennex, Inc.
7. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
8. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations
9. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
10. U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
11. Egenix Licenses Harvard Anti-Cancer Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/9/2016)... Paris Police Prefecture and ... ensure the safety of people and operations in several locations ... Teleste, an international technology group specialised in broadband ... its video security solution will be utilised by ... across the country. The system roll-out is scheduled for the ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):